An observational study in Rhizarthrosis, sponsored by Clinique Bizet. Recruiting at 1 site in France. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Clinique Bizet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Rhizarthrosis is a form of osteoarthritis that affects the trapeziometacarpal joint at the base of the thumb, which is more common in women over 50. Genetic and hormonal factors as well as the frequency of certain physical movements may contribute to its appearance. Surgical treatment is recommended if medical treatment fails, and trapezectomy is currently considered the standard method, although 3rd generation trapeziometacarpal prostheses are also available.
The aim of this study is to compare the clinical and radiographic results after surgical treatment of rhizarthrosis: prosthesis versus trapezectomy.
This is a two-center, randomized, prospective, comparative study.
The functional, clinical and radiographic evaluation in the early, medium and long term will make it possible to determine the possible superiority of arthroplasty if it exists.
The close evaluation of the patients during the first 3 months will make it possible to update the superiority of the arthroplasty on the functional recovery in the short term if it exists.
Clinique Bizet is the lead sponsor of 16 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with symptomatic disabling osteoarthritis in failure of medical treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Trapezectomy group
Arthroplasty group
Device: HORUS
The trapezium-metacarpal arthroplasty consists of the installation of a bipolar prosthesis composed of a metacarpal implant and a trapezial implant articulated through a metacarpal "head".
patient assessment of the wrist
Quick-Dash score (11 minimum value and 55 is maximum )
Time frame: 4 weeks
patient assessment of the wrist pain
Visual Analogical Assessment score (0 no pain 10 severe pain)
Time frame: 4 weeks
Started Nov 2023 (actual). Primary completion is estimated for Dec 2027, 49 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinique Bizet